{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "KYMR",
  "name": "Kymera Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/KYMR/",
  "json_url": "https://frontierpicks.com/dossiers/KYMR.json",
  "status": "RECENTLY_EXITED",
  "current_conviction": "LOW",
  "graded_conviction": "NONE",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing, stretched theme structurally supported on a pullback to the $100 shelf rather than into the catalyst gap.",
  "invalidation_trigger": "A weekly close below $100 forfeits the post-BROADEN2 breakout base; secondary confirmation if the I&I/derm M&A theme goes quiet (no follow-on bid after AbbVie–Apogee) alongside a second analyst downgrade following RBC's 7/13 cut.",
  "catalyst_date": "2026-08-26",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-07-02",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue on products: all reported revenue is collaboration and milestone income, so the quarterly revenue line is lumpy and is not a demand signal.",
    "Q2 2026's $65.0M revenue was a $45M Gilead option-exercise fee plus a $20M Sanofi milestone — both non-recurring, neither tied to KT-621.",
    "BROADEN2 topline is guided 'by year-end 2026' with no fixed date and no stated pre-announcement convention, so it can print in any week of Q4.",
    "Insider and venture-fund sales run through Rule 10b5-1 plans adopted in December 2025 and on 2026-03-24, so they are pre-scheduled rather than discretionary.",
    "Sanofi is both a Kymera collaboration partner and the funder of Recludix's rival oral STAT6 program, so Sanofi news can cut in either direction.",
    "Clinical leadership changed on 2026-07-27: Terence Rooney is CMO; predecessor Jared Gollob remains an advisor only through the end of 2026."
  ],
  "body_markdown": "## Current Thesis\n\nThe narrative leg has not changed: KT-621, a once-daily oral STAT6 degrader aimed at the IL-4/IL-13 axis that injectable biologics own today, with BROADEN2 Phase 2b atopic-dermatitis topline guided \"by year-end 2026\" after enrollment closed roughly six months early on 2026-06-25 — three days after AbbVie agreed to buy Apogee Therapeutics for $10.9B on 2026-06-22.\n\nWhat has advanced since the last note is two sessions of tape and nothing else. The 2026-08-19 close of $127.31 marked the 52-week high; 2026-08-21 closed $119.80; the 2026-08-24 close of $121.05 recovered 1.04% of that and sits 4.9% under the high. The three-month price change reads +49.9%, down from +51.9% at the prior reading and +57.9% at the high. RSI(14) is 76.2 against 78.2 on 2026-08-21 — the momentum reading cooled by two points while price went up.\n\nEstimates are frozen. The 24-analyst consensus target is $130.91, the same figure carried since 2026-08-14; the implied upside stockanalysis.com computes against it is 8.15% at $121.05, narrower than the 9.27% it showed at $119.80. That gap moves with the quote, not with the estimates.\n\nThe company has published nothing since the 2026-08-05 Q2 results. A check of the StockTitan tape on 2026-08-25 still returns 2026-08-05, 2026-07-28 and 2026-07-27 as the three most recent items — twenty calendar days of silence into the back half of August.\n\nThe narrative is **saturated**. The acceleration window was 2026-06-22 to 2026-06-25. The target-raise wave ran 2026-06-26 (Canaccord $129) through 2026-07-16 (Mizuho $140), then turned two-way: RBC to Sector Perform $115 on 2026-07-13, Deutsche Bank initiating Hold at $120 on 2026-07-30, and a 2026-08-07 cluster at J.P. Morgan $121, Bank of America $123 (cut from $125) and Wells Fargo $116. Piper Sandler's 2026-08-20 maintain at $140 is the most recent action on the ratings table as of 2026-08-25 and it left the average untouched.\n\n## Bull Case\n\n- BROADEN2 runs to the clock set on 2026-06-25: roughly 200 patients aged 12–75 with moderate-to-severe atopic dermatitis, three KT-621 doses against placebo over 16 weeks, primary endpoint percent change from baseline in EASI at Week 16. Phase 3 initiation in AD is guided by mid-2027, subject to regulator discussions.\n- The 2026-08-05 quarter converted partnerships into cash: collaboration revenue $65.0M against $11.5M in Q2 2025 and a $31.165M consensus, comprising a $45M Gilead option-exercise fee on KT-200 and a $20M Sanofi milestone on KT-485/SAR447971 entering Phase 1. EPS -$0.62 versus a -$0.72 estimate.\n- No financing event has surfaced: cash, equivalents and investments of $1.5B at 2026-06-30, runway reiterated into 2029, no offering alongside the 2026-08-05 results and none on the tape through the 2026-08-25 check — twenty days of a 52-week-high tape that has not been used to print equity.\n- The pipeline tightened rather than slipped at the 2026-08-05 update: KT-579, an oral IRF5 degrader, moved from \"2H-2026\" to Phase 1 healthy-volunteer data in 4Q26; the BREADTH Phase 2b asthma readout stands at late 2027.\n- The upper tail of the published target distribution still sits above the last close: B. Riley $155 (2026-06-29), Piper Sandler $140 (2026-08-20), Mizuho $140 (2026-07-16), Barclays $139 (2026-08-06), Stifel $132 (2026-08-13).\n- That is a positioning overhang capable of supplying bid on a clean Q4 print.\n\n## Bear Case\n\n- Three of the five most recent brokerage actions carry targets below the 2026-08-19 high of $127.31 — Wells Fargo $116 (2026-08-07), J.P. Morgan $121 (2026-08-07), Bank of America $123 cut from $125 (2026-08-07). The 24-analyst average of $130.91 leaves 8.15% between the 2026-08-24 close and where the sell-side collectively marks the name.\n- The upgrade cycle stopped in mid-July. RBC downgraded to Sector Perform on 2026-07-13 while raising its target to $115, and Deutsche Bank started coverage at Hold on 2026-07-30. Since then the only action is a maintain.\n- There is no scheduled company event between now and the guided readout window. BROADEN2 topline is \"by year-end 2026\" with no fixed date; the next reporting obligation is the Q3 print, historically early November. A binary with no date can decay for a quarter.\n- Q2 R&D expense of $119.5M against $78.4M a year earlier means burn is scaling ahead of the data. The into-2029 runway assumes no plan expansion alongside a mid-2027 Phase 3 build, and a stock within 5% of its 52-week high is the natural window for an ATM or a shelf.\n- Revenue quality: the entire $65.0M Q2 line was two non-recurring partner payments. Q3 will be the first quarter without them, and neither had anything to do with KT-621.\n- Competitive clock: Sanofi funds Recludix's rival oral STAT6 program while simultaneously partnering Kymera on KT-485. Clean rival Phase 1 data would compress both the differentiation argument and the acquirer list.\n\n## Setup & Price Structure\n\nThe advance that matters started from the 2026-08-03 close of $100.31 and ran to $127.31 on 2026-08-19 — the 52-week high — before two down sessions to $119.80 on 2026-08-21 and a 1.04% recovery to $121.05 on 2026-08-24. Distance from the high is 4.9%. The shelf that would define a broken structure is the roughly $100 area from early August; nothing between there and the high has been tested twice.\n\nCrowding and positioning observables, stated as observables:\n\n- RSI(14) at 76.2 on 2026-08-24, above 70 through the whole August leg, and 78.2 as recently as 2026-08-21. Price rebounded while the oscillator eased.\n- Consensus target $130.91 unchanged since 2026-08-14 across 24 analysts, so upside to the published average is now 8.15% — the number compresses purely as price rises.\n- The first reading spanning the run to the high is due around 2026-08-26.\n- Beta 1.96 (stockanalysis.com statistics page, 2026-08-04) — the name amplifies the biotech tape in both directions.\n- No earnings inside the next 30 days; the last print was 2026-08-05 and the next is expected in early November, so there is no scheduled fundamental checkpoint against a +49.9% three-month move.\n- Insider and venture-fund selling runs through Rule 10b5-1 plans adopted in December 2025 and on 2026-03-24, which makes those sales pre-scheduled rather than a discretionary read on price.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-26 (est.)** — FINRA short-interest publication covering the 2026-08-14 settlement date. First positioning reading that spans the advance from $100.31 on 2026-08-03 toward the 2026-08-19 high of $127.31.\n- **~2026-09-11 (est.)** — FINRA short-interest publication covering the 2026-08-31 settlement date. Second post-run reading; separates cover-driven bid from fresh long demand.\n- **2026-09-30** — EADV Congress opens in Vienna (runs to 2026-10-03). Kymera delivered a late-breaking KT-621 presentation at EADV on 2025-09-17; no 2026 slot appears on the company tape as of the 2026-08-25 check.\n\n## Elapsed catalysts\n\n- **No company-scheduled event inside the window.** As of 2026-08-25 there is no press release after 2026-08-05, no conference-participation announcement and no data date on the calendar before EADV. *(passed 1d ago)*\n\n## What Would Change Our Mind\n\nThe structure that would have to fail is the base built off the 2026-08-03 close of $100.31 — the launch pad for the entire August leg. A weekly close below $100 forfeits it and puts the name back inside the July range, where the two-way analyst action lives. That is the gradeable condition.\n\nSecond, the catalyst gap. If the ~2026-11-04 Q3 update again declines to narrow \"by year-end 2026\" to a month, and EADV opens 2026-09-30 with no Kymera late-breaker, the readout stays undated through an entire quarter while burn runs at the Q2 rate of $119.5M in R&D.\n\nThird, the takeout premium. It was created by AbbVie–Apogee on 2026-06-22. If the September–October window passes with no further dermatology or type-2 immunology bid, that component of the multiple has nothing supporting it.\n\nOn the other side: a shelf takedown or ATM utilisation disclosed in the Q3 10-Q would confirm the issuance-into-strength risk, while BROADEN2 topline landing early with Week 16 EASI inside the injectable benchmark range would restart an estimate cycle that has been static since 2026-08-14.\n\n## Correlation Notes\n\n- **I&I M&A read-through.** The re-rating dates to AbbVie's $10.9B Apogee agreement on 2026-06-22, so the name trades with dermatology and type-2 immunology deal flow rather than with its own newsflow — it has had none for twenty days.\n- **Sanofi cuts both ways.** Sanofi paid the $20M KT-485 milestone booked in Q2 2026 and funds Recludix's competing oral STAT6 asset. A Sanofi immunology headline is not directionally predictable for KYMR.\n- **Injectable comps set the bar.** Dupilumab-class Week 16 EASI performance is the benchmark BROADEN2 gets judged against, which links the readout's reception to Regeneron/Sanofi commercial datapoints.\n\n- **Partner concentration.** Gilead ($45M option exercise on KT-200) and Sanofi are the two names that have written cheques this year; a change in either collaboration re-prices the non-KT-621 half of the story.",
  "first_seen": "2026-06-26",
  "last_analyzed": "2026-08-25T03:23:41+00:00",
  "last_synthesized": "2026-08-25",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}